DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story

starstarstarstarstar (1)
Log in or Register to rate this News Story
Forward Printable StoryPrint Comment

 

 

Molecular Imaging Homepage

New PET imaging method may yield benefits over FDG for detecting certain cancers Gallium-68-labeled FAPI tracer yields promising results

Dr. David Wong Professor recognized for contributions to PET and Theranostics

SVSR unveils Siemens Horizon PET/CT trailer Putting a small and powerful scanner on a coach

Philips to manage medical imaging equipment for Aussie providers for 20 years First-of-its-kind partnership in Australia and ASEAN Pacific region

Under AMG, Piramal Imaging changes name to Life Molecular Imaging LMI is being run within the Alliance Medical Molecular Imaging division

RadioMedix Inc. and Curium to develop and commercialize PET agent 64Cu-Dotatate for use in suspected neuroendocrine tumors

Dr. Sanjiv Gambhir Stanford’s chair of radiology wins Cassen Prize

Researchers undertake 'largest brain study' using 60,000 SPECT images Evaluate accelerated brain aging in scans

SNMMI proposes solutions to Ga-68 generator shortage Combating waiting periods of between 14 and 18 months

Tc-99m generator production resumes in Australia Follows month and a half shutdown due to conveyor belt issue

Peter Webner

Peter Webner

Cyclopharma appoints new Chief Executive Officer
January 10, 2018
Clermont-Ferrand (France) and Indianapolis (United-States), January 10, 2017 - Cyclopharma today announced that its Board has approved a change in the company’s US leadership. Peter Webner is appointed as CEO of Cyclopharma US Corp, effective Jan. 1st, 2018, while Bernard Landes will remain Chairman of the Board.

Peter Webner will drive the development of Cyclopharma’s pipeline of new companion diagnostic PET tracers for oncology in the US. His first objective will be to ensure EstroTep’s US FDA submission and approval and access to the US market by the end of 2019. EstroTep is a PET tracer approved for use in France which is indicated in metastatic breast cancer.

Story Continues Below Advertisement

Servicing GE Nuclear Medicine equipment with OEM trained engineers

We offer full service contracts, PM contracts, rapid response, time and material,camera relocation. Nuclear medicine equipment service provider since 1975. Click or call now for more information 800 96 NUMED



"I am honored to take on the challenge of building a US division for Cyclopharma. The immediate task at hand is getting EstroTep filed with the FDA and making it available upon approval", said Peter. "Cyclopharma has a history of investing in novel targeted companion diagnostics that are valuable in guiding clinical decision making. The company has a solid pipeline of products and clinical targets which will be launched in the future. We believe in a bright future for Molecular Imaging and look forward to providing additional diagnostic tools to use."

Bernard commented "We are very pleased to have Peter join the team. As our first US based employee he brings a considerable and complementary experience to the Cyclopharma team that will enable us to accelerate our US development plans while actively contributing to building our pipeline of companion diagnostic PET tracers for oncology."

Peter Webner was Senior Vice President, Manufacturing and Sales for Zevacor Molecular and Interim Executive Vice President for Zevacor Pharma. A certified nuclear medicine technologist, Mr. Webner has over 25 years of experience in nuclear medicine and molecular imaging, focused on with a wide range of responsibilities. Building on clinical and administrative experience gained at Mt. Sinai Medical Center in New York, he has held key positions in sales, marketing, product development and management with Eastern Isotopes, IBA Molecular, Positron Corporation, NCM, and Zevacor Molecular and Zevacor Pharma. Mr. Webner earned his BA in Radiological Health Sciences at Manhattan College and completed advanced studies in product development at the Harvard Graduate School of Business.


About Cyclopharma
Since its creation in 2000, Cyclopharma has developed molecular imaging solutions to allow the observation of cell function in vivo as part of the targeted treatment of cancer, in order to improve individualized treatment plans for patients in terms of diagnostics, monitoring and therapeutic effectiveness, whilst also reducing costs.

With more than 120 employees and revenue of €23 million, Cyclopharma invests more than 10% of revenue in research into novel molecular imaging tracers. Since 2015 it has built on dense and balanced geographical coverage to drive international growth, with the aim of becoming a major European force in personalized medicine

Molecular Imaging Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED